Sociedad Americana de Hirudoterapia

The history of leeching and hirudin

Research article published in Haemostasis (1991)

Última actualización: March 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Desarrollo de fármacosFarmacología salivalGenómica y proteómicaFields W · Haemostasis, 1991

Abstract

Leeching is an art dating back at least to ancient Egypt. It reached its zenith in the late 18th and early 19th centuries. The antithrombotic quality of leech saliva was first noted by Haycraft in 1884 and the active anticoagulant ingredient isolated in 1904 by Jacoby. He gave this agent the name 'hirudin'. Hirudin was isolated in pure crystalline form by Markwardt in 1957 and first produced in quantity by genetic engineering in 1986. The salivary glands of several species of leech also contain other biologically active substances which are currently undergoing investigation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeHistorical ArticleJournal Article
Indexed MeSH termsAnimalsBloodlettingHirudin TherapyHirudinsHistory, 15th CenturyHistory, 16th CenturyHistory, 17th CenturyHistory, 18th CenturyHistory, 19th CenturyHistory, 20th CenturyHistory, AncientHistory, Medieval

Resumen

Leeching is an art dating back at least to ancient Egypt. It reached its zenith in the late 18th and early 19th centuries.

Por qué esto importa para la hirudoterapia

Relevant to the development and clinical application of leech-derived pharmaceutical compounds.

Citación

The history of leeching and hirudin.

Fields W · Haemostasis, 1991

Contexto clínico relacionado

Añadido a la biblioteca ASH: March 18, 2026 · Última actualización del sitio: March 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

The history of leeching and hirudin | ASH